Skip to content

Acupuncture treatment for chronic atrophic gastritis: a randomized controlled trial

Acupuncture treatment for chronic atrophic gastritis: a randomized controlled trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025000225
Enrollment
Unknown
Registered
2025-02-08
Start date
2025-02-21
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic atrophic gastritis

Interventions

sham acupuncture group:sham acupuncture
acupuncture group:acupuncture

Sponsors

School of Acupuncture-Moxibustion and Tuina Beijing University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Male or female patients aged 18 to 70 years; 2. Patients who meet the diagnostic criteria for CAG based on gastroscopy and pathology results; 3. Patients who meet the diagnostic criteria of Traditional Chinese Medicine (TCM) for syndromes including liver-stomach qi stagnation syndrome damp-heat in the spleen and stomach syndrome and yin deficiency of stomach syndrome; 4. Patients with at least one of the symptoms including epigastric pain abdominal distension postprandial fullness early satiety acid regurgitation and belching; 5. Patients without acupuncture treatment in the past 3 months; 6. Patients who are able and willing to provide informed consent and to attend treatment.

Exclusion criteria

Exclusion criteria: 1. Patients with peptic ulcers specific types of gastritis (such as autoimmune gastritis) or gastrointestinal bleeding; 2. Patients who tested positive for C-13 urea breath test at the time of enrollment (Hp infected patients); 3. Patients who have undergone abdominal or gastrointestinal surgery in the past six months; 4. Patients with severe cardio-cerebrovascular liver kidney hematological diseases malignant tumors or other life-threatening diseases; 5. Patients who have used any medications that may affect the function of the digestive tract including prokinetic agents mucosal protectants and antacids in the past 2 weeks; 6. Patients with scars or injuries at the acupoints skin diseases infectious diseases or peripheral neuropathy; 7. Patients with impaired consciousness difficulty participating in the trial or mental illness; 8. Pregnant or planning to be pregnant women and breastfeeding women; 9. Patients with a history of alcohol drinking or drug abuse.

Design outcomes

Primary

MeasureTime frame
Gastrointestinal Symptom Rating Scale;Gastric mucosal pathological tissue score;

Secondary

MeasureTime frame
Depression and anxiety assessment;Gastrointestinal Symptom Rating Scale at other time points;Credibility and expectation evaluation;Blinding assessment;Changes in OLGA and OLGIM scores;Quality of life score;Changes in Single-cell transcriptome before and after treatment;

Countries

China

Contacts

Public ContactCun-zhi Liu

School of Acupuncture-Moxibustion and Tuina Beijing University of Chinese Medicine

lcz_tg@126.com+86 10 5391 2201

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026